AlphAIAlphAI — Financial news for AI agents
investing.comNOV 43 min read$HRMY

Harmony Q3 2026 slides: WAKIX nears $1B despite profit pressure

Harmony Biosciences (HRMY) reported Q3 2026 revenue of $268.9M, up 12% YoY, but missed EPS estimates ($0.81 vs. $1.11). WAKIX sales grew to $269M, while pipeline drug BP-205 showed promising Phase 1 results. Shares fell 8.32% post-earnings due to margin pressure from higher royalties and milestone charges.

Original reporting
investing.com
Published Nov 4, 2026, 4:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 4:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$HRMY
Bearish
high confidence
Mentioned
$HRMY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HRMYBearishHigh
01

Why it matters

The earnings miss triggered an 8.3% share decline, suggesting short-term downside risk while pipeline advancements may support longer-term upside.

02

Market read

Primary earnings disclosure with material miss; immediate price impact and implications for biotech sector margins.

03

What to watch

Potential upside from upcoming BP-205 data and long-term WAKIX revenue trajectory could offset short-term margin concerns.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Harmony Biosciences presented its Q3 2026 results, showing revenue growth but an earnings miss due to higher royalties and a $25M milestone charge.

Company-level read

Ticker impact

$HRMYBearishHigh confidence
Context

Harmony Biosciences reported Q3 2026 earnings miss; EPS $0.81 vs $1.11 estimate, shares fell 8.3% after results.

Expected impact

downward pressure as market prices in margin compression and earnings shortfall

Evidence & confidence

The miss was larger than consensus and accompanied by a notable share decline, indicating immediate sell pressure.

Market effects

Sector

Highlights margin pressure risk for niche biotech firms relying on royalty-heavy licensing deals.

Regional

US biotech sector may see modest pullback as earnings miss spreads.

Global

Limited to investors tracking specialty pharma earnings.

Counterpoint

What could challenge this read

Long investors may view the dip as an overreaction given strong revenue growth and pipeline progress.

Key entities

  • company
    Harmony Biosciences Holdings

    US-listed biotech company (NASDAQ:HRMY) focused on narcolepsy drug WAKIX and pipeline candidate BP-205.

Read at source← All news

StoryHarmony Biosciences posts Q3 revenue growth but EPS miss, shares slide

Also covered by

2 outlets

Related articles

NOV 4
$HRMYMed

Harmony Biosciences 3Q 2026: Revenue $268.92M, Net income $48.2M, EPS $0.81— 10-Q Summary

Harmony Biosciences reported Q3 2026 revenue of $268.92M, up 12.3% YoY, but net income fell 5.2% to $48.2M and EPS declined 6.9% to $0.81. WAKIX revenue grew 12.3% in the quarter, driven by higher shipments and a price increase. The FDA accepted the Pitolisant GR NDA for review, with a target PDUFA date of April 1, 2027. Phase 3 trials for EPX-100 and Pitolisant HD are ongoing, with results expected in 2027. The company also began a Phase 1b study of BP-205.

tradingview.com1 min
NOV 4
$HRMYMedAI 8/10

Harmony Biosciences Reports Q3 Financial Results

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile ​ WAKIX ® Net Revenue in Q3 of $2

SEC EDGAR 8-K2 min